Medindia

X

Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer

by Dr. Trupti Shirole on  February 20, 2015 at 12:32 AM Cancer News   - G J E 4
A new study has revealed that a combination of chemotherapy and treatment with two drugs, Perjeta and Herceptin, lengthens survival of patients with HER2-positive metastatic breast cancer by an average of nearly 16 months.
 Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer
Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer
Advertisement

Lead researcher Dr. Sandra M. Swain said, "We've never seen results like this before in HER2-positive metastatic breast cancer. This unprecedented data gives patients with an aggressive disease hope to live a longer, better life."

Advertisement
During the study, patients received either Perjeta with Herceptin and chemotherapy or placebo with Herceptin and chemotherapy in the control group. The median overall survival for patients who received the Perjeta with Herceptin and chemotherapy was 56.5 months, compared with 40.8 months for those in the control group, a difference of 15.7 months. The study also revealed that the patients' cancer did not get worse for 6.3 months longer in the Perjeta group.

The study is published in the 'New England Journal of Medicine'.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All